Searched for
ICHNOS
Glenmark shares gain 2% as firm receives $700 million upfront payment from AbbVie dealGlenmark Pharmaceuticals' shares surged following its subsidiary's $700 million upfront payment from AbbVie for an exclusive licensing agre...- Glenmark Pharmaceuticals targets 70% branded portfolio by 2030, boosts focus on novel drugsGlenmark Pharmaceuticals is transitioning into an innovation-driven company over the next 4-5 years, emphasizing its novel drug portfolio a...
- Glenmark surges 20% after major drug licensing deal with AbbVieGlenmark Pharmaceuticals shares surged following a significant licensing agreement. Ichnos Glenmark Innovation partnered with AbbVie for a ...
- Glenmark Pharma shares rally 14% on AbbVie boost; analysts hike targets to Rs 2,800Glenmark Pharma surged 14% after its subsidiary signed a $700 million licensing deal with AbbVie for its experimental cancer drug, ISB 2001...
- Glenmark Pharmaceuticals shares rally up to 20%, mutual funds lead the charge over retail investorsThe shares of Glenmark Pharmaceuticals surged 20% on Friday, July 11, to a day’s high of Rs 2,286 following a landmark $2 billion licensing...
- Motilal Oswal sees 28% upside in Glenmark Pharma, hails $700 mln cancer drug deal as ‘new era’ for innovation playGlenmark Pharma shares: The brokerage noted that the agreement—executed through Glenmark’s subsidiary, Ichnos Glenmark Innovation (IGI)—“va...
- Glenmark Pharma hits 10% upper circuit, scales fresh 52-week high on $700 mn cancer drug dealGlenmark Pharma Share Price: Glenmark Pharmaceuticals' shares soared after its subsidiary, Ichnos Glenmark Innovation, inked a global licen...
- Glenmark, AbbVie ink $700 million drug licensing dealGlenmark Pharmaceuticals has entered into a significant agreement with AbbVie to commercialize its investigational drug, ISB 2001, targetin...
- Glenmark’s blood cancer drug ISB 2001 shows promising results in trialIchnos Glenmark Innovation's ISB 2001 has shown promising results in treating relapsed or refractory multiple myeloma (RRMM), demonstrating...
- Glenmark Pharma shares up 2% after FDA grants fast track status to cancer drugGlenmark Pharma's innovation arm, IGI, received FDA fast track designation for its myeloma therapy ISB 2001, targeting heavily pre-treated ...
- US prospects, new drugs make Glenmark look betterGlenmark's marketing portfolio as of December 2024 had 201 generic products authorised for distribution in the US. The company has 51 appli...
- Glenmark forms alliance with Ichnos to develop anti-cancer drugsGlenmark Pharmaceuticals and Ichnos Sciences have formed an alliance called Ichnos Glenmark Innovation (IGI) to accelerate cancer drug disc...
- Glenmark reports Rs 403 crore loss in Q4FY23For the fourth quarter of FY23, Glenmark’s consolidated revenue was at Rs. 3374 crore as against Rs.3019 crore in the same quarter of previ...
- Buy Glenmark Pharmaceuticals, target price Rs 580: Nomura, IndiaGlenmark Pharmaceuticals, incorporated in the year 1977, is a Mid Cap company (having a market cap of Rs 12152.98 Crore) operating in Pharm...
- Glenmark bets on respiratory drug, licensing deals to improve businessGlenmark had gross debt of ₹3,765 crore as of June 30, 2022. The company over the years accumulated debt to fund its innovation-led R&D and...
- Glenmark looks to license out second drug assetGlenmark chairman and managing director Glenn Saldanha said one of the corporate objectives of the Mumbai-headquartered company is to do at...
- Glenmark's subsidiary Ichnos Sciences enters pact with Almirall for novel drug to treat autoimmune diseasesUnder the agreement, Almirall is granted global rights to develop and commercialize this monoclonal antibody for autoimmune diseases. Ichno...
- Add Glenmark Pharmaceuticals, target price Rs 607: ICICI SecuritiesGlenmark Pharmaceuticals Ltd., incorporated in the year 1977, is a Mid Cap company (having a market cap of Rs 14885.78 Crore) operating in ...
- Glenmark soars over 21% on CLSA’s upgradeThe stock has fallen over 42 per cent in the last one year.
- Glenmark Pharma jumps 21% on CLSA upgradeYES Securities is also positive on Glenmark Pharma with a 12-month target price of Rs 340.
Load More
